Mounjaro's mode of action: how tirzepatide works in the body

You've heard it called a 'hunger jab', here's what's actually happening

Most people encounter Mounjaro through a shorthand that doesn't quite fit: 'the hunger jab', 'the skinny jab', descriptions that make it sound like a simple off switch for appetite. The reality is more precise, and more interesting. Tirzepatide (Mounjaro's active ingredient) is what pharmacologists call a dual incretin receptor agonist. It binds to and activates receptors for two hormones your gut already produces: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). Both are released naturally when you eat. Their job, in part, is to signal satiety to the brain, regulate insulin release, and slow gastric emptying so nutrients are absorbed steadily. Tirzepatide mimics and amplifies those signals, and does so at both receptor types at the same time.

That distinction matters. The mode of action of tirzepatide differs from older GLP-1 medicines like semaglutide, which target the GLP-1 receptor alone. Early research suggested GIP activation might even enhance the GLP-1 effect rather than simply adding a parallel signal, though the exact interplay is still being studied. What the clinical trials showed, published in the SURMOUNT-1 paper in the New England Journal of Medicine, was weight loss averaging around 20–21% of body weight at the highest dose over 72 weeks, a figure that placed tirzepatide ahead of any previously licensed weight-management medicine.

The tirzepatide overview on this site goes into the clinical programme in more depth if you want the full picture alongside the mechanism.

What the GIP and GLP-1 pathways each contribute

A question our prescribers hear most weeks is some version of: "If GLP-1 medicines already work, what does adding GIP actually do?" It's a fair question. Here's what we know from the available evidence.

GLP-1 receptor activation has well-documented effects on appetite and satiety, signals reach the hypothalamus, the brain region involved in hunger regulation, reducing the drive to eat. It also slows gastric emptying, meaning food sits in the stomach longer, and you feel fuller for longer after a meal. GLP-1 additionally promotes insulin secretion in a glucose-dependent way, meaning it only does so when blood sugar is actually raised, which is why hypoglycaemia is not a significant risk for people without diabetes taking these medicines.

GIP receptor activation appears to work alongside GLP-1 on satiety signalling, and there is evidence it may enhance the appetite-reducing effect rather than simply repeating it. GIP receptors are also found in fat tissue, where GIP may influence fat metabolism directly, though the exact clinical significance of this pathway in humans is an active area of research. The NHS medicines page for tirzepatide on nhs.uk describes both mechanisms in accessible terms and is worth reading alongside the SmPC if you want the patient-level detail.

Put together, activating both receptors produces a combined effect on appetite, gastric emptying and metabolic signalling that the trial data suggest goes beyond what either receptor alone would achieve. That is the core of what makes tirzepatide's mechanism of action distinctive among licensed weight-management medicines in the UK.

How the mechanism translates to the dosing schedule

Understanding the mode of action also explains why the dosing structure is designed the way it is. Treatment begins at 2.5mg, a dose chosen specifically to let the body adjust to the receptor activation gradually, reducing the likelihood of gastrointestinal side effects in the early weeks. The therapeutic effect builds as the dose is increased, typically in four-weekly steps, up to a maximum of 15mg. Your prescriber decides the pace of titration based on how your body responds.

The gastric-emptying effect is strongest in the early weeks of any new dose and generally settles as the body adapts. This is why nausea and digestive symptoms are most common in the period after starting or after a dose increase, and tend to ease over days to weeks, the mechanism hasn't changed, but the response to it has stabilised. If you're curious about when tirzepatide starts working, the timing follows directly from this biology.

Mounjaro is taken as a once-weekly subcutaneous injection via a pre-filled KwikPen, each pen containing four doses. Storage is in the fridge (2–8°C); the precise room-temperature window is set out in the Patient Information Leaflet, which your prescriber will point you to. The injection sites (abdomen, thigh, or upper arm) should be rotated each week.

For anyone thinking about whether this medicine might be appropriate for them, the Mounjaro overview covers eligibility, the prescription process, and what a consultation involves. Private treatment through a regulated online pharmacy is one route for people who don't meet current NHS criteria or prefer not to wait. Cost context for private treatment is covered on our weight-loss treatments page.

What tirzepatide's mechanism doesn't do, and why that matters

One thing worth being clear about, because it often surprises people: tirzepatide is not a stimulant. It doesn't speed up the heart, suppress appetite through a central nervous system stimulant pathway, or produce the kind of effects associated with older weight-loss medicines like amphetamine derivatives. The mechanism works with the body's own incretin system, hormones that were already there, already doing this job, just at lower levels than the medicine produces.

It also isn't a fat-digestion blocker, which is how orlistat works. And it doesn't act on serotonin pathways, which older medicines sometimes targeted. The tirzepatide mode of action is specific to the GIP and GLP-1 receptor system.

This specificity matters for understanding the side-effect profile too. Most common side effects (nausea, constipation, looser stools, indigestion) follow directly from the gastric-emptying mechanism. They are not random; they are predictable consequences of the pathway the medicine uses. Serious but less common effects, including acute pancreatitis, have been flagged in MHRA safety communications and require awareness: severe stomach pain that radiates to the back needs prompt medical attention.

If you want to read more about how tirzepatide acts across its receptor targets or about how long it stays active after each dose, those pages go deeper into the pharmacology. These are prescription-only medicines, suitability is always a clinical decision, not a self-assessment.